CONCLUSION

• Abluminus DES+ demonstrated promising safety and efficacy in real-world patients.
• The clinical outcomes in complex patient cohorts are very encouraging warrants the use of Abluminus DES+ in complex patients too.

  • Principal Investigator
    Dr. Sameer Dani
  • 2,500
    Patients
  • 2,495 (99.8%)
    Patients completed 1 year follow-up
  • 2,246 (89.8%) Patients
    completed 2 years follow-up
STUDY DESIGN

• To evaluate the safety and efficacy of the Abluminus DES+ in an all-comers population with minimal exclusion criteria.
• Multicenter, prospective, all-comers ongoing registry performed in 31 centers in India.
• Ambulatory visits or telephone contact at 1 month, 9 months, 1 year and yearly up to 5 years after the index procedure.

Study Endpoints:

Primary Endpoints:
• Major Adverse Cardiac Events (MACE) is composite of Cardiac Death, Target Vessel MI (TV-MI), Target Lesion/ Vessel Revascularization (TLR/ TVR) at 1 year follow-up.

Secondary Endpoints:
• Stent Thrombosis (ST) according to the ARC definition calculated at any time point; MACE assessed up to 3 years.

CLINICAL ENDPOINTS AT 1 YEAR
DESIGNED TO TREAT DIABETIC PATIENTS
DIABETICS FROM en-ABL e-Registry
CLINICAL ENDPOINTS AT 1 YEAR
DESIGNED TO TREAT AMI PATIENTS
AMI PATIENTS FROM en-ABL e-REGISTRY
CLINICAL ENDPOINTS AT 1 YEAR